Your browser doesn't support javascript.
loading
Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma.
Ferté, C; Besse, B; Dansin, E; Parent, F; Buisine, M-P; Copin, M-C; Penel, N; Soria, J-C.
Afiliação
  • Ferté C; SITEP (Phase I Unit), Department of Medical Oncology, Institut Gustave Roussy, Villejuif; General Oncology Department, Centre Oscar Lambret, Lille.
  • Besse B; Department of Medical Oncology, Institut Gustave Roussy, Villejuif.
  • Dansin E; General Oncology Department, Centre Oscar Lambret, Lille.
  • Parent F; Department of Pneumology, Antoine Beclere Hospital, Assistance Publique-Hopitaux de Paris, Clamart.
  • Buisine MP; Molecular Biology Laboratory (Oncology Unit), Centre Hospitalier Universitaire Régional, Lille.
  • Copin MC; Department of Pathology, CHRU, Lille, France.
  • Penel N; General Oncology Department, Centre Oscar Lambret, Lille.
  • Soria JC; SITEP (Phase I Unit), Department of Medical Oncology, Institut Gustave Roussy, Villejuif. Electronic address: soria@igr.fr.
Ann Oncol ; 21(6): 1385-1387, 2010 Jun.
Article em En | MEDLINE | ID: mdl-20501506
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quinazolinas / Adenocarcinoma / Proteínas Proto-Oncogênicas / Proteínas ras / Neoplasias Pulmonares Limite: Humans Idioma: En Ano de publicação: 2010 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quinazolinas / Adenocarcinoma / Proteínas Proto-Oncogênicas / Proteínas ras / Neoplasias Pulmonares Limite: Humans Idioma: En Ano de publicação: 2010 Tipo de documento: Article